Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upBarbara Eichhorst, Ulrich Mey, Michael Hallek et al.|Annals of Oncology|2020Cited by 568
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Eva Hoster, Jeanette K. Doorduijn et al.|The Lancet|2024Cited by 135
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in SwitzerlandAlden A. Moccia, Felicitas Hitz, Stefanie Aeppli et al.|Hematological Oncology|2020Cited by 15
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Vindi Jurinović et al.|Hematological Oncology|2025Cited by 1
265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECTSimone Ragaini, Marco Ladetto, Riccardo Moia et al.|Hematological Oncology|2025Cited by 1